Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 6 of about 6   

Articles published

DVAX 26.23 -0.17 (-0.64%)
price chart
Dynavax Gets Crushed After Advisory Committee Vote
In after-hours trading, we saw an enormous drop in shares of Dynavax (Nasdaq: DVAX) that caught my attention due to the severity of the drop and the huge amount of fuss over the incident.
Dynavax Falls After Vaccine Fails to Win Panel Backing  Bloomberg
Analysts At William Blair Maintain Outperform On Dynavax Technologies
In a research note issued last week, William Blair Maintained coverage with an "Outperform" rating on Dynavax Technologies (DVAX), and a one-year price target of $9 a share, representing a premium of 122% to DVAX stock closing price of $4.06. Dynavax's ...
Despite Safety Concerns, Dynavax's Heplisav Should Receive FDA Approval
Dynavax originally published on the adjuvant role of 1018 ISS in 1997. Its findings were further supported by another publication that has been cited more than 850 times.
Dynavax's Heplisav Vaccine Works on Hepatitis B, FDA Says
Dynavax Technologies Corp.'s Heplisav vaccine works against the contagious liver disease hepatitis B, Food and Drug Administration staff said.
Why Dynavax's HEPLISAV Is Likely To Be Approved: Impact On Future Vaccine ...
Dynavax's (NASDAQ:DVAX) HEPLISAV had an FDA Advisory Committee on November 15, 2012. The Advisory Committee voted 13 to one that HEPLISAV data adequately demonstrated immunogenicity.
European Stocks Drop; Yen Weakens to Six-Month Low
Dynavax Technologies Corp. slid 47 percent after its hepatitis B vaccine failed to win the backing of U.S. regulatory advisers.